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Abstract
Although they have become a widely used experimental technique for identifying differentially expressed (DE) genes, DNA
microarrays are notorious for generating noisy data. A common strategy for mitigating the effects of noise is to perform
many experimental replicates. This approach is often costly and sometimes impossible given limited resources; thus,
analytical methods are needed which increase accuracy at no additional cost. One inexpensive source of microarray
replicates comes from prior work: to date, data from hundreds of thousands of microarray experiments are in the public
domain. Although these data assay a wide range of conditions, they cannot be used directly to inform any particular
experiment and are thus ignored by most DE gene methods. We present the SVD Augmented Gene expression Analysis
Tool (SAGAT), a mathematically principled, data-driven approach for identifying DE genes. SAGAT increases the power of a
microarray experiment by using observed coexpression relationships from publicly available microarray datasets to reduce
uncertainty in individual genes’ expression measurements. We tested the method on three well-replicated human
microarray datasets and demonstrate that use of SAGAT increased effective sample sizes by as many as 2.72 arrays. We
applied SAGAT to unpublished data from a microarray study investigating transcriptional responses to insulin resistance,
resulting in a 50% increase in the number of significant genes detected. We evaluated 11 (58%) of these genes
experimentally using qPCR, confirming the directions of expression change for all 11 and statistical significance for three.
Use of SAGAT revealed coherent biological changes in three pathways: inflammation, differentiation, and fatty acid
synthesis, furthering our molecular understanding of a type 2 diabetes risk factor. We envision SAGAT as a means to
maximize the potential for biological discovery from subtle transcriptional responses, and we provide it as a freely available
software package that is immediately applicable to any human microarray study.
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Introduction
Since their inception over 13 years ago [1], DNA microarrays
have become a staple experimental tool used primarily for
exploring the effects of biological interventions on gene expression.
Microarrays have enabled a range of experimental queries,
including a survey of gene expression across dozens of mammalian
tissues [2], a comparison of human cancers in over 2000 tumor
samples [3], and the identification of differentially expressed (DE)
genes between pairs of conditions. Identifying DE genes is
especially common, as it is often the first means of characterizing
differences between two poorly understood conditions. As of 2009,
there are publicly available microarray data for w2400 human
conditions (at the Gene Expression Omnibus [4]). These data
make possible a huge number of pairwise comparisons for DE
gene analysis. Given this sizable opportunity for biological
discovery, we focus our attention on the task of DE gene
identification.
Microarrays are notorious for generating noisy or irreproducible
data [5–8]. This is partially due to the inherent technical noise of
the experiment, which can be modeled and often removed from
the resulting data. However, biological noise also plays a
significant role, and effects of this noise source are not as easily
corrected [9]. A common solution to biological noise involves
replicating the experiment many times in order to ‘‘average out’’
noise effects. In the context of DE gene prediction, we define a
replicate as a biologically independent comparison of RNA levels
between the experimental conditions of interest. Unfortunately,
assay cost and a limited supply of biological material often limit the
efficacy of a replication-based strategy. To circumvent these
difficulties, we need analytical methods which increase DE gene
prediction accuracy at no additional cost.
One inexpensive source of microarray replicates comes from
prior experiments. In the last decade, researchers have generated
data from hundreds of thousands of microarrays, and many of these
are publicly available at repositories like the Gene Expression
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referred to as ‘‘knowledge’’) represent exact replicates of data from a
novel study (referred to as ‘‘data’’), but a subset of these experiments
may describe similar underlying biology and could be considered
‘‘partial replicates’’. Because it is not clear a priori which of the prior
experiments (if any) would qualify as partial replicates, pre-existing
microarray knowledge cannot be used directly to identify DE genes
in a novel dataset.
It is therefore worth considering indirect methods for using this
knowledge. Two previously existing methods use microarray
knowledge to compute more accurate variance estimates for each
gene [10,11]. Both methods replace sample variance estimates for
each gene by gene-specific variances calculated across a compen-
dium of microarrays from GEO. This approach was shown to be
most useful with small data sample sizes, and no further benefits
were seen when the microarray knowledge exceeded *250 arrays.
A different approach might involve identifying transcriptional
modules: groups of genes that exhibit coordinated or correlated
expression changes across a range of conditions. A complete and
accurate understanding of module structure would reveal
expression dependencies between genes, such that on average,
genes in the same module would be coexpressed more often than
genes chosen at random. Thus, knowledge of one gene’s
expression would confer information about the expression of the
other genes in the module. Several studies [12–18] have used
microarray knowledge to identify transcriptional modules. Of
these, five have been tested on yeast datasets of 1000 arrays or
fewer [12–14,16,17] and one has been applied to *2000 human
cancer datasets [15]. Only one [18] was applied to a diverse
human microarray knowledge set, in this case containing *2500
arrays. Given that tens of thousands of arrays are publicly
available for some individual microarray platforms, a larger-scale
identification of transcriptional modules is certainly possible.
Knowledge of transcriptional modules and their constituent
genes is not directly applicable to DE gene identification, and most
existing methods ignore these relationships. Of the few that
provide a means to incorporate expression modules [19–21], none
provide a mechanism for extracting these modules from large-scale
microarray knowledge sets. Consequently, there is a need for a
method that can identify relevant transcriptional modules from
huge compendia of microarray knowledge and use this informa-
tion to better predict DE genes.
In this work, we present the SVD Augmented Gene expression
Analysis Tool (SAGAT), a mathematical approach that identifies
expression modules from microarray knowledge and combines
these with novel data to identify DE genes. To accomplish these
tasks, SAGAT employs Singular Value Decomposition (SVD)
in concert with pseudoinverse projection. SVD has been used
previously to decompose microarray knowledge into mathemat-
ically independent transcriptional modules (eigengenes) and the
corresponding independent cellular states where these modules are
active (eigenarrays) [22]. Most non-SVD module-finding methods
identify discrete modules where module membership for each gene
is a binary feature. In contrast, SVD assigns a continuously-valued
weight for each gene, which allows varying strengths of co-
expression to be present in the same module and genes to be part
of multiple modules. SVD models the expression of each gene as a
linear combination of the eigengenes’ expressions, and a number
of studies have used this technique to define modules on smaller
scales. Raychaudhuri et al. [23] and Alter et al. [22] each initially
applied SVD (the former in the form of PCA) to yeast time course
data to identify fundamental modes of expression response that
vary over time. The latter study also demonstrated the ability of
SVD to remove noise or experimental artifacts present in the data.
Shortly thereafter, Troyanskaya et al. [24] used SVD to identify
eigengenes in gene expression data for the purposes of missing
value estimation. Alter and colleagues subsequently employed
generalized [25] and higher order [26] versions of SVD for the
integration and decomposition of heterogeneous microarray
datasets. Horvath and Dong [27] used SVD of microarray data
in combination with coexpression analysis to generate eigengene
coexpression networks. Finally, in a large scale study, SVD was
shown to reduce noise when used in the integration of disparate
microarray datasets [28].
The technique of pseudoinverse projection has also previously
been applied to genome-scale data. Alter and Golub demonstrated
the utility of SVD coupled with pseudoinverse projection by
reconstructing one genomic dataset in terms of the eigenarrays of
another [29]. This enabled the observation of a set of cellular states
in one dataset that were also manifested in the other. Subsequent
work used pseudoinverse projection in concert with an alternative
matrix decomposition technique (non-negative matrix factorization)
to classify gene expression states ofoneorganism interms ofanother
[30]. In the current work, using SAGAT, we combine SVD-derived
modules, pseudoinverse projection, and a rigorous statistical model
toadjustgeneexpression errorestimatesinadatasetofinterest.This
yields a knowledge-informed differential expression score for each
gene.
We demonstrate SAGAT in several ways. First, we investigate
whether transcriptional modules are readily detectable in a large
compendium of microarray knowledge. Second, we test SAGAT
on a range of simulated datasets to assay its performance with
respect to a known gold standard. Third, we evaluate SAGAT’s
ability to increase DE gene predictive power in three highly
replicated real world datasets. Finally, we apply SAGAT to a new
human dataset investigating transcriptional profiles in the setting
of insulin resistance (IR), a risk factor for type 2 diabetes. Though
a known relationship exists between obesity and insulin resistance
[31,32], it is not always consistent [33,34]; in addition, many
studies characterizing IR do not deconvolve the effects of obesity
[35]. This novel microarray dataset builds upon previous work
[35–37] to investigate obesity-independent transcriptional effects
of insulin resistance. We illustrate the improved sensitivity of
SAGAT over existing methods by identifying IR candidate DE
Author Summary
Though the use of microarrays to identify differentially
expressed (DE) genes has become commonplace, it is still
not a trivial task. Microarray data are notorious for being
noisy, and current DE gene methods do not fully utilize
pre-existing biological knowledge to help control this
noise. One such source of knowledge is the vast number of
publicly available microarray datasets. To leverage this
information, we have developed the SVD Augmented
Gene expression Analysis Tool (SAGAT) for identifying DE
genes. SAGAT extracts transcriptional modules from
publicly available microarray data and integrates this
information with a dataset of interest. We explore SAGAT’s
ability to improve DE gene identification on simulated
data, and we validate the method on three highly
replicated biological datasets. Finally, we demonstrate
SAGAT’s effectiveness on a novel human dataset investi-
gating the transcriptional response to insulin resistance.
Use of SAGAT leads to an increased number of insulin
resistant candidate genes, and we validate a subset of
these with qPCR. We provide SAGAT as an open source R
package that is applicable to any human microarray study.
SAGAT
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assays. Results of this analysis contribute to a more comprehensive
molecular understanding of human insulin resistance.
Results
Modularity of Gene Expression Data
To demonstrate that transcriptional modules are detectable in a
multi-condition microarray knowledge compendium, we charac-
terized the degree of modularity in a collection of 4440 arrays from
the HGU95Av2 platform. We consider an expression module a
group of genes exhibiting coordinated expression across some
subset of the entire compendium. Genes in such a group will have
relatively large positive or negative pairwise covariances; thus,
degree of modularity refers to the number of genes in the
compendium that belong to one or more groups of significantly
covarying genes.
Figure 1A displays a binarized representation of the sample
covariance matrix for the entire HGU95Av2 compendium,
whereby each covariance value whose magnitude is w:25 is
colored black (white otherwise). This matrix was then subjected to
hierarchical biclustering (Figure 1B), which resulted in many
blocks of nonzero binary covariance, ranging in size from a few
genes to nearly 1000. Furthermore, this covariance pattern does
not appear to be due to chance, as the biclustering results from 100
randomized knowledge matrices (see Materials and Methods)
showed no covariance blocks exceeding a 15 gene cutoff.
To parameterize a simulation study (details below), we used a
1000-gene compendium to characterizee the mean number of
genes per module, the mean percentage of DE genes found in
modules, and the mean percentage of non-DE genes found in
modules. This was achieved by subsetting the HGU95Av2
compendium and coupling it with a human prostate cancer
dataset [38]. The mean number of genes per module was 15, the
mean percentage of DE genes found in modules was 60% (673/
1122), and the mean percentage of non-DE genes found in
modules was 47% (3752/7983). These values were employed in
the simulation study that follows.
Singular Value Decomposition (SVD) of Gene Expression
Data
SVD identifies eigengenes whose expression is mutually
orthogonal across all arrays in the compendium. To demonstrate
that mathematical orthogonality correlates with biological orthog-
onality (as manifested by biologically independent eigengenes), we
performed a Gene Ontology (GO) term enrichment analysis of a
subset of the eigengenes from the HGU95Av2 compendium (using
the gene weights of each eigengene as scores). Table 1 displays the
top three significant Biological Process terms with fewer than 500
annotated genes for eigengenes 1–5, 10, 20, 50, and 200. The
terms within each eigengene are largely consistent, and each
eigengene describes a relatively distinct biological process. We
note that there is not an absolute correspondence between the
modules displayed in Figure 1B and the eigengenes identified by
SVD, as the methods used to identify these structures are
algorithmically different. However, we detected substantial overlap
in the enriched Biological Process terms associated with the largest
covariance modules and highest ranking eigengenes (e.g. the
largest module and first eigengene were both strongly enriched for
translation and biosynthesis terms).
Simulation Study
We first tested the validity of the SAGAT model using simulated
data. We simulated knowledge compendia with structures ranging
from that shown in Figure 2A, where 60 of the 100 DE genes are
in 15-gene modules and none of the 900 non-DE genes are, to that
shown in Figure 2C, where the same number of DE genes are in
modules and all 900 non-DE genes are also. Figure 2B depicts a
modularity structure that is approximately equivalent to that of the
prostate cancer dataset, where 60% of prostate cancer DE genes
are found in modules and 47% of non-DE prostate cancer genes
are found in modules.
After running SVD on each simulated compendium to calculate
the appropriate W matrix, we tested SAGAT on all combinations
of data and knowledge. As SAGAT relies on a single parameter
specifying the number of eigengenes (M), we first estimated the
optimal value for this parameter by trying all possible values on
Figure 1. Modularity characterization of HGU95Av2 compendium. (A) All pairwise covariances were calculated between 9105 genes; entries
whose absolute values were greater than .25 were set to one and colored black (set to zero and colored white otherwise). (B) Binarized covariance
matrix after hierarchical biclustering ( 1{binary covariance ½  distance metric and complete linkage) to identify coordinated expression modules. The
observed modularity is not due to chance, as an identical procedure applied to a randomized expression matrix showed no covariance blocks larger
than a few genes (not shown).
doi:10.1371/journal.pcbi.1000718.g001
SAGAT
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The best performance was achieved with M~200; we used this
value for all subsequent simulation runs.
Figure 3 displays results from running SAGAT on two
compendia with modularity structures identical to Figures 2A
(3A,3B) and 2B (3C,3D) coupled with datasets having either
one or 15 replicates. The mean AUC improvement over the
fold change metric (Mean D), ranging from .0042 to .0708, is
shown. Within the range of structures bounded by these two
compendia and for both sample sizes, SAGAT consistently
improves the AUC of DE gene prediction. The two trends
observed are: (1) increasing performance improvement with
decreasing numbers of array replicates, and (2) increasing
performance improvement with decreasing numbers of non-DE
gene modules. Performance begins to degrade below that of fold
change if the simulated compendia adopt modularity structures
between those of Figures 2B and C (results not shown), but we
have evidence suggesting that the modularity of real world datasets
resemble configurations falling between Figures 2A and B (see
Discussion).
To demonstrate that use of SAGAT could yield improved
statistical power without concurrently increasing the false positive
rate of prediction, we repeated the above experiments using true
positive rate (TPR) evaluated at a fixed false positive rate (FPR) of
.05 (in place of AUC). These results are shown in Figure S3, and
the performance improvements with respect to fold change closely
resemble those displayed in Figure 3.
Highly Replicated Real Datasets
To evaluate SAGAT performance on real data, we tested it on
subsets of three highly replicated human microarray datasets (see
Materials and Methods for details). As a gold standard, we used
either the fold change or limma t [39] metrics to identify significant
DE genes from each dataset in its entirety; this resulted in 1122
(12.3%), 588 (4.4%), and 6002 (29.9%) DE genes for the prostate
cancer, letrozole treatment (GEO ID: GSE5462), and colorectal
cancer (GSE8671) datasets, respectively.
After downloading the three corresponding knowledge com-
pendia (minus the highly replicated datasets) and running SVD
on each, we determined the optimal number of eigengenes by
Table 1. GO Biological Process enrichment of HGU95Av2 compendium eigengenes.
Eigengene Term ID Name # genes p-value
1 GO:0006412 Translation 271 v1|10{30
GO:0009059 Macromolecule biosynthetic process 431 1:90|10{23
GO:0006396 RNA processing 269 1:20|10{20
2 GO:0000278 Mitotic cell cycle 203 7:20|10{7
GO:0022403 Cell cycle phase 223 3:40|10{6
GO:0000279 M phase 172 1:10|10{5
3 GO:0007155 Cell adhesion 494 2:60|10{12
GO:0006955 Immune response 481 2:70|10{12
GO:0000902 Cell morphogenesis 305 6:20|10{10
4 GO:0042110 T cell activation 86 3:60|10{8
GO:0046649 Lymphocyte activation 128 6:90|10{6
GO:0045321 Leukocyte activation 145 1:20|10{5
5 GO:0022403 Cell cycle phase 223 1:50|10{8
GO:0000278 Mitotic cell cycle 203 1:50|10{8
GO:0007067 Mitosis 131 2:80|10{8
10 GO:0006941 Striated muscle contraction 27 1:00|10{4
GO:0016567 Protein ubiquitination 43 9:10|10{4
GO:0006936 Muscle contraction 130 1:22|10{3
20 GO:0006323 DNA packaging 177 1:10|10{3
GO:0006997 Nuclear organization and biogenesis 22 2:50|10{3
GO:0006325 Establishment of chromatin architecture 171 2:90|10{3
50 GO:0008354 Germ cell migration 6 2:60|10{3
GO:0050764 Regulation of phagocytosis 6 3:30|10{3
GO:0007067 Positive regulation of phagocytosis 6 3:30|10{3
200 GO:0009187 Cyclic nucleotide metabolic process 35 3:40|10{4
GO:0009605 Response to external stimulus 424 5:70|10{4
GO:0030193 Regulation of blood coagulation 11 6:60|10{4
A Kolmogorov-Smirnov (K-S) test was used to evaluate the significance of enrichment. The member genes of each eigengene were ranked by the absolute value of their
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SAGAT run on two non-overlapping subsets of this dataset and
the HGU95Av2 compendium while varying the number of
eigengenes (parameter M). The AUCs of the fold change metric
are displayed as red horizontal lines. SAGAT outperforms fold
change for many values of M, and for both subsets there is a
distinct maximum in the AUC curve for a particular value of the
parameter. For these two subsets and several others tested (not
shown), the optimal value for M is approximately half the number
of arrays in the compendium. We used this value for subsequent
analyses on all datasets and compendia, which translates to 2220,
7238, and 6108 eigengenes for the HGU95Av2, HGU133A, and
HGU133plus2.0 platforms, respectively. To show that SAGAT’s
performance as a function of M was not due to chance, we
randomized the expression values of the compendium and re-ran
the same test in Figure 4B. These results are shown in gray. In this
case, SAGAT never outperforms fold change, suggesting that the
performance improvement from the original compendium is not
spurious.
Next we applied SAGAT to multiple subsets of each of the three
datasets. Figure 5 displays the performance of SAGAT coupled
with the appropriate W matrices. For comparison, we feature
AUC differences with respect to fold change of both SAGAT and
Figure 2. Modularity structures of simulated microarray compendia. Simulated compendia ranged from containing only DE gene modules
(A) to having DE gene plus the maximum number of non-DE gene modules (C). (B) This configuration represents a conservative approximation of the
structure of a real biological dataset (see Discussion).
doi:10.1371/journal.pcbi.1000718.g002
Figure 3. SAGAT performance on four simulated data-knowl-
edge configurations. In each panel, both SAGAT and the fold change
metric were applied to 200 simulated datasets consisting of either one
[(A) and (B)] or 15 replicates [(C) and (D)]; the AUC improvement
achieved by SAGAT over fold change is displayed for each. In (A) and
(C), a simulated knowledge compendium matching Figure 2A was used
by SAGAT; in (B) and (D) the simulated knowledge corresponds to
Figure 2B. On average, SAGAT outperforms fold change in all four cases
with the mean improvement located at the top of each panel. The
simulated knowledge structure for (B) and (D) represents a conservative
approximation of the structure of a real biological dataset (see
Discussion).
doi:10.1371/journal.pcbi.1000718.g003
Figure 4. Identifying the optimal number of eigengenes. (A) and
(B) show SAGAT performance versus varying numbers of eigengenes
(parameter M) when applied to two non-overlapping four-array subsets
of the prostate cancer dataset. The HGU95Av2 knowledge compendium
was used for this task. The red horizontal lines denote the performance
of the fold change metric. In both cases, M set to approximately half the
number of arrays in the compendium leads to the best performance;
this point is marked with green vertical lines. In (B), the light gray points
display SAGAT performance when using a randomized knowledge
compendium; this suggests that SAGAT improvement over fold change
is not due to chance.
doi:10.1371/journal.pcbi.1000718.g004
SAGAT
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prostate cancer dataset using a fold change and limma t-derived
gold standard, yielding mean AUC improvements of .023 and
.018, respectively. Given that the relative performance trends are
similar, Figures 5C and D show performance on the letrozole
treatment and colorectal cancer datasets using only the fold
change-derived gold standard, yielding AUC improvements of
.009 and .019, respectively. In all three datasets, irrespective of
sample size, SAGAT nearly always improves the AUC over fold
change; in cases where this does not occur, AUC is left essentially
unchanged. In contrast, the t-statistic consistently lowers the AUC
of DE gene prediction and is not applicable when the number of
replicates is 1. Though the limma t performance improves when
using a limma t gold standard, it is still unable to outperform the
other two metrics. AUC improvement for SAGAT generally
decreases with increasing sample size, and the improvement is
largest for the prostate cancer and colorectal cancer datasets.
To express the performance of SAGAT in a more tangible
form, we estimated the effective number of arrays added by using
the method. Table 2 shows results for each of the three highly
replicated datasets at four initial sample sizes. On average, with
one exception in 12 tests, use of SAGAT always increased the
effective number of arrays. In some cases, this improvement was
quite significant: a two-array prostate cancer subset coupled with
SAGAT effectively performed as well as a 4.72 array dataset. As
before, the number of arrays added generally decreases with
increasing sample size.
As with the simulated data, we also repeated the highly
replicated dataset experiments using TPR calculated at an FPR of
.05 as an evaluation metric. These results are displayed in Figure
S4, and the performance improvements very closely resemble
those shown in Figure 5.
Comparison to Related Method
We evaluated the GEO method (both standard and ‘‘voting’’
methods) on the prostate cancer dataset and HGU95Av2
compendium and compared its performance to SAGAT. Figure
S1 shows the results, which demonstrate that SAGAT (and fold
change) outperform the GEO method in much the same way as
when compared to the limma t-statistic above.
Figure 5. SAGAT, fold change, and limma t performance on subsets of three highly replicated human datasets. In each panel, the gold
standard was defined as the top 1122, 588, and 6002 highest scoring genes for the prostate cancer, letrozole treatment, and colorectal cancer
datasets, respectively. (A) The fold change metric was used to rank genes for the gold standard. SAGAT (with HGU95Av2 compendium), fold change,
and limma t were run on all combinations of n=1, 2, 5, and 15 replicate subsets and the performance improvement of SAGAT and limma t over fold
change displayed. Limma t requires two or more replicates to score genes. (B) Identical conditions as (A), with the limma t metric used to rank gold
standard genes. (C) and (D) Similar plots for the letrozole treatment (HGU133A compendium) and colorectal cancer (HGU133plus2.0 compendium)
datasets, respectively. Fold change was used to rank gold standard genes in these panels. In all cases, SAGAT performs as well or better than the fold
change and limma t metrics, while the limma t nearly always yields the poorest performance.
doi:10.1371/journal.pcbi.1000718.g005
SAGAT
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compendium size. As Figure S2 shows, SAGAT continues to
improve performance as the compendium increases to its full size.
The performance begins to level off near 4400 arrays, but further
improvement would still be expected with an even larger
compendium.
Insulin Resistance Dataset
Given encouraging performance of SAGAT on simulated and
real human datasets, we applied it to an unpublished experimental
dataset investigating expression differences between human insulin
resistant and insulin sensitive adipose tissue. The obesity-
independent relationship between insulin resistance and adipose
gene expression has previously been characterized on a small scale
[40], but no large-scale studies have attempted to decouple the
effects of obesity from insulin resistance [35]. In this experimental
design, patients were otherwise healthy and matched for levels of
obesity; thus, we expected to identify more subtle expression
changes associated with insulin sensitivity status.
As detailed in Materials and Methods, the same 12 pairs of
RNA samples were applied to three different microarray
platforms: Affymetrix, Agilent, and Illumina. We initially attempt-
ed to identify DE genes using the limma t metric on data from each
platform individually. After correcting the results for multiple tests,
we did not detect any significant genes at a .05 FDR cutoff. Next,
we integrated results from all three platforms to try to capture
subtle but consistent signals. We applied the method of Rank
Products (RP) [41] to lists of genes ranked by either fold change or
SAGAT. Table 3 shows results from this procedure. As we wanted
to evaluate only the most confident predictions, we corrected for
multiple testing by controlling the PFER (per family error rate).
This is a strict multiple hypothesis test correction method that is
generally more conservative than the FDR (false discovery rate) or
FWER (family wise error rate) [42]. A total of 19 genes were found
to be significantly DE at a PFER of .05. When ranking genes by
fold change before applying RP, 12 genes were found to be
significantly DE—five upregulated and seven downregulated.
When using SAGAT to rank the genes instead, 18 genes were
significantly DE—seven upregulated and 11 downregulated.
SAGAT with RP detected all but one of the genes found using
fold change with RP, and seven genes were identified only through
use of SAGAT. We refer to the 11 genes detected by both fold
change and SAGAT rankings as Group I; Group II genes are
those that were detected exclusively using SAGAT.
We searched the literature for evidence implicating the genes of
Table 3 in insulin resistance, diabetes, or fatty acid metabolism (an
important function of adipose tissue). Genes for which evidence
was found are marked with an asterisk. Four of the Group I genes
[FOSB (Entrez Gene ID: 2354), FADS1 (3992), SELE (6401),
PPBP (5473)] had some literature describing their involvement;
five of the Group II genes [ATP1A2 (Entrez Gene ID: 477), FASN
(2194), FOS (2353), CXCR4 (7852), ELOVL6 (79071)] were also
implicated.
To experimentally validate these candidates, we performed
quantitative RT-PCR (qPCR) using 23 of the original 24 RNA
samples subjected to an amplification reaction. We tested 11 of the
19 genes from Table 3: five from Group I and six from Group II.
We also tested four genes that were not significant by Rank
Products; these genes serve as negative controls. For each gene, we
calculated the mean log2 fold change over the b-actin (Entrez
Gene ID: 60) housekeeping gene for the insulin resistant and
insulin sensitive samples. Results are displayed in Figure 6. Of
the Group I and II genes tested, all had qPCR expression
differences that matched the direction of those identified using
Rank Products.
We then tested the significance of each gene’s expression
difference using a Wilcoxon rank-sum test. Three of the genes had
p-values smaller than a .05 threshold: CSN1S1 (Entrez Gene ID:
1446), FOSB, and CXCR4 (marked by asterisks in Figure 6). The
first two genes are from Group I; the third is from Group II. Of
the four negative controls tested, none were found significantly
different in expression between the two groups.
Discussion
In this work, we present SAGAT, a principled method for
integrating pre-existing microarray knowledge with a dataset of
interest to identify DE genes. From prior knowledge, SAGAT
extracts ‘‘eigengenes’’, or mathematically independent transcrip-
tional modules, which collectively describe observed expression
dependencies between genes. These dependencies are combined
with the expression changes of each gene in the data to form the
SAGAT score, which enables expression information to be shared
between genes that are coexpressed in the knowledge.
To validate SAGAT, we first demonstrated that a compendium
of microarray knowledge showed significant modularity. This
result, which was not sensitive to varying compendium sizes (not
shown), was not surprising, as it has been shown before on
knowledge sets of a smaller scale. Nevertheless, it was not clear
whether such modules would be detectable on a much larger and
more heterogeneous collection of microarrays.
Next, we demonstrated favorable SAGAT performance in
identifying DE genes on a series of simulated datasets. We note
that our model for simulating data represents an oversimplification
of realistic coexpression relationships between genes (see Materials
Table 2. Effective number of arrays when using SAGAT on three human datasets.
Prostate cancer Letrozole treatment* Colorectal cancer
# Initial
arrays Min Mean Max Min Mean Max Min Mean Max
2 2.32 3.66 4.72 2.28 2.90 4.24 2.20 2.92 3.59
4 4.43 5.66 6.59 3.97 4.74 5.81 4.13 4.92 5.56
10 10.77 11.21 11.91 9.95 10.52 11.27 10.13 10.68 11.22
30 30.14 30.87 31.70 29.45 30.08 30.58 28.89 29.00 29.10
AUC values from Figure 5 were converted to effective numbers of arrays by creating a ‘‘standard curve’’ of AUC versus sample size and interpolating (see Materials and
Methods section for details).
*Results in the last row of the Letrozole treatment section were calculated using 28 initial arrays.
doi:10.1371/journal.pcbi.1000718.t002
SAGAT
PLoS Computational Biology | www.ploscompbiol.org 7 March 2010 | Volume 6 | Issue 3 | e1000718and Methods), but with it we can create distinct numbers of
modules in DE and non-DE genes to test the limits of SAGAT
performance. As detailed in the Results, SAGAT most improves
performance with respect to the fold change metric when
transcriptional modules are only composed of DE genes. As the
number of non-DE gene modules increases, the performance
improvement decreases, but at a realistic ratio of DE gene modules
to non-DE gene modules (Figure 2B, which closely matches the
configuration of the prostate cancer dataset), SAGAT still
outperforms fold change for all numbers of replicates tested.
We evaluated SAGAT on three highly replicated microarray
datasets. We chose datasets with many replicates so we could
approximate a gold standard DE gene list for each one. Ideally,
results from an independent and more accurate experiment like
quantitative RT-PCR would provide the DE gene truth for a given
dataset, but quantifying expression differences of every gene on a
microarray would be prohibitively expensive. Instead, we assume
that for each of the three datasets, the number of replicates is large
enough that DE genes calculated using fold change on all arrays is
approximately correct. Then the task becomes using small (often
noisy) subsets of each dataset to predict the true DE genes. We
applied the fold change, limma t, and SAGAT metrics to multiple
non-overlapping subsets of varying numbers of replicates. SAGAT
always outperforms the t-statistic, often by a large margin. With
sample sizes of only 1 replicate, the limma t is not applicable as it
requires a fold change variance estimate. Compared to fold
change, SAGAT nearly always better identifies DE genes; in the
worst case it leaves performance unchanged. These results suggest
that SAGAT would be consistently beneficial for predicting DE
genes from a dataset of interest. Importantly, the results displayed
in Figure S4 demonstrate that use of SAGAT leads to improved
statistical power at a small fixed false positive rate, which is a
necessity for the effective analysis of high-throughput biological
experiments.
We expressed SAGAT’s performance improvement over fold
change in terms of the effective number of arrays added. This
shows that, except in a small number of cases, use of SAGAT
always increases the effective sample size of an experiment. In
some cases this increase is substantial: for one two-array subset of
the prostate cancer dataset, the effective sample size became 4.72
arrays, or more than double the initial sample size of the
experiment. As expected, the number of arrays added decreases as
the initial number of arrays increases, due in part to the lower
capacity for prediction improvement when starting with a larger
sample size.
We also demonstrated that SAGAT outperforms the related
GEO method when evaluated on the prostate cancer dataset. As
even the fold change method consistently outperforms the GEO
method, it appears that more accurate estimation of gene
variances is not the most effective way to improve performance
for this dataset. In contrast, use of gene module information from
an SVD of microarray knowledge gives consistent improvement
over fold change.
We determined the sensitivity of SAGAT performance to the
number of arrays in the knowledge compendium. It was shown in
[11] that the GEO method does not give further performance
improvement when knowledge exceeds *250 arrays. To com-
pare, we evaluated the effect of compendium size on SAGAT






FOSB* FBJ murine osteosarcoma viral oncogene homolog B Up v1e{4 v1e{4
ACTG2 actin, gamma 2, smooth muscle, enteric Down 0.0007 0.0007
FADS1* fatty acid desaturase 1 Down 0.0022 0.0048
PMP2 peripheral myelin protein 2 Down 0.0034 0.0770
ATP1A2* ATPase, Na+=K+ transporting, alpha 2 Down 0.0040 0.1620
CNN1 calponin 1, basic, smooth muscle Down 0.0067 0.0114
CSN1S1 casein alpha s1 Down 0.0123 0.0004
SELE* selectin E (endothelial adhesion molecule 1) Up 0.0174 0.0006
CASQ2 calsequestrin 2 (cardiac muscle) Down 0.0176 0.0238
FAM150B family with sequence similarity 150, member B Down 0.0188 0.0006
FASN* fatty acid synthase Down 0.0231 0.0610
FOS* v-fos FBJ osteosarcoma viral oncogene homolog Up 0.0242 0.0885
SRGN serglycin Up 0.0249 0.6952
CILP cartilage intermediate layer protein Up 0.0271 0.0420
CXCR4* chemokine (C-X-C motif) receptor 4 Up 0.0311 0.6058
PPBP* pro-platelet basic protein (chemokine ligand 7) Down 0.0325 0.0355
AADAC arylacetamide deacetylase (esterase) Up 0.0374 0.0019
ELOVL6* long chain fatty acid elongation Down 0.0425 0.0734
IL6* interleukin 6 (interferon, beta 2) Up 0.1340 0.0120
Significance was determined by running the Rank Products (RP) algorithm on ranked lists of genes derived from Affymetrix, Agilent, and Illumina microarray data. Genes
were ranked by both fold change and SAGAT before applying RP; the PFER (per family error rate) is displayed for both cases. Only those genes with a PFER of .05 or
smaller (achieved using SAGAT or fold change) are considered significant. Genes in normal font were significant using both fold change and SAGAT, genes in bold were
identified only with SAGAT, and IL6 was found only with the fold change metric.
*Literature evidence implicates gene with insulin resistance, diabetes, or fatty acid metabolism.
doi:10.1371/journal.pcbi.1000718.t003
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method, SAGAT continues to improve performance as the
compendium increases in size. The improvement starts leveling
off near the compendium’s full size (4400 arrays), but an even
larger knowledge compendium should still give better perfor-
mance. Thus, SAGAT is able to extract useful information from
much larger microarray compendia than the GEO method.
Given SAGAT’s potential to improve DE gene identification,
we applied the method to a novel insulin resistance dataset
obtained from three different microarray platforms. An initial
attempt to identify DE genes on each platform separately yielded
no candidates, suggesting that the transcriptional response in
question was noisy and/or subtle. A Gene Ontology term
enrichment analysis on data from each platform consistently
identified terms related to immune response (results not shown),
implying that a reproducible biological signal was present in the
data. To improve the signal to noise ratio at the gene level, we
used the method of Rank Products (RP) across all three platforms
to identify subtly but consistently changing DE genes.
An application of RP to genes ranked by fold change yielded 12
DE gene candidates with a per family error rate of .05 or smaller.
A similar analysis on genes ranked by SAGAT yielded 18 genes,
11 of which overlapped with the fold change list. This suggests that
the incorporation of transcriptional module information resulted
in an increased sensitivity to detecting DE genes. We intentionally
used a very strict significance threshold to select a small number of
DE genes that were most consistently changed (and which
hopefully represent true biological differences), but relaxation of
this threshold would lead to additional candidates.
We next performed a literature search on each significant gene
for information implicating it in insulin resistance, diabetes, or fatty
acid metabolism. This uncovered evidence for multiple genes from
three biological processes: inflammation [SELE, IL6 (Entrez Gene
ID: 3569), PPBP, CXCR4], cell differentiation [FOSB, FOS], and
fatty acid synthesis [FADS1, FASN, ELOVL6] [43–45]. A role for
inflammation in IR has previously been suggested by a similar study
[35], but of the four pro-inflammatory genes listed above only IL6
was also detected in that work. In this study, SELE, IL6, and
CXCR4 were upregulated in insulin resistant patients, reinforcing
the positive role of inflammation in IR.
Cell differentiation has also been implicated in insulin resistance
in the sense that insulin resistant adipose tissue displayed lower
expression of differentiation markers than their insulin sensitive
counterparts [37]. In this work FOSB and FOS were upregulated
in IR, which is compatible with the above since both gene
products have been shown to trigger de-differentiation [46,47].
Fatty acid synthesis has long been known to be relevant to
insulin resistance [48]. The details of this relationship are not
always consistent: FADS1 is known to be downregulated in IR
[49], while ELOVL6 has shown the opposite effect [50] and
FASN has shown conflicting results [51]. To our knowledge, no
single study has analyzed the effects of all three of these fatty acid
synthesis genes with respect to insulin resistance in adipose tissue.
Our results show a coherent decrease in the gene expression of all
three genes, suggesting that obesity-independent insulin resistance
is associated with altered fatty acid synthesis and storage in adipose
tissue. We speculate that such an occurrence may lead to
inappropriate fatty acid accumulation elsewhere (i.e. circulating
in serum), which has been known to lead to IR [51]. One
explanation for the inconsistent results in previous studies is the
potentially confounding effects of obesity (a condition where fatty
acid synthesis increases) and insulin resistance. The current study
explicitly attempts to remove the former effect.
Taken together, the above results emphasize the importance of
increased inflammation, differentiation, and decreased fatty acid
synthesis to adipose tissue-based insulin resistance. We note that
our confidence in this assertion was greatly helped by SAGAT, as
four of the nine genes involved in these processes were only
identified using this method. This is particularly true for genes like
CXCR4, whose PFER received a substantial boost upon
application of SAGAT (0.6058 to 0.0311). We expect that further
experimentation will reveal the precise relationships between these
processes and IR.
The remaining significant genes detected only by SAGAT
exhibited varying levels of insulin resistance-related literature
evidence. ATP1A2, which codes for an ATPase, was previously
found to be differentially expressed between insulin resistant and
insulin sensitive muscle tissue, though in the opposite direction
than was found in this study [52]. PMP2 (Entrez Gene ID: 5375)
and SRGN (5552), coding for a myelin protein and hematopoietic
proteoglycan, respectively, lack any literature evidence for a
relationship to IR; illumination of their specific roles would require
further study.
To confirm the validity of some of the above DE gene
candidates, we performed qPCR using RNA samples from 23 of
the original 24 patients (one IR sample did not have sufficient
RNA for the procedure). We tested five genes found to be
significant using both fold change and SAGAT, six genes found
only with SAGAT, and four negative controls. All of the qPCR
expression differences of the non-control genes matched the
direction of those from the microarray data, suggesting that these
changes are reproducible. We then tested the significance of these
changes using a Wilcoxon rank-sum test (RST). We note that the
Figure 6. Quantitative PCR validation of insulin resistance
candidate genes. Fifteen genes were tested for differential expression
between 11 out of the original 12 insulin resistant samples and all 12
original insulin sensitive samples using TaqMan Real-time PCR. The first
five genes came from predictions of both fold change and SAGAT, the
next six were suggested by SAGAT only, and the last four genes served
as negative controls. The directionality of differential expression of all
non-control genes was in agreement between the microarray and qPCR
data. Three DE genes were statistically significant according to qPCR:
CSN1S1, FOSB, and CXCR4.
doi:10.1371/journal.pcbi.1000718.g006
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[53], and we anticipated noisy data due to the amplification
reactions needed prior to qPCR (see Materials and Methods
section). Nevertheless, three genes—two identified by fold change
and SAGAT, one by only SAGAT—were found to be significant.
In contrast, none of the negative control genes showed significant
expression differences. Combining the qPCR results together with
the literature evidence implicating four of the eight genes not
confirmed by qPCR suggests a false positive rate of 0.4 (2/5) for
fold change and 0.36 (4/11) for SAGAT. Though the difference
between these values may not be statistically significant, this result
suggests that SAGAT was able to improve the sensitivity of DE
gene detection in this experiment without increasing the false
positive rate. We did not explicitly test IL6 using qPCR, although
we note that previous work has shown this gene to be over-
expressed in insulin resistant adipose tissue [35]. This is the only
gene detected using fold change that was not also detected using
SAGAT, which may reflect discordant expression patterns of IL-6
between previously existing datasets and this one.
We now explore the means by which SAGAT improves pre-
diction of DE genes. Results from the simulation study demonstrate
that the method improves performance to the extent that DE genes
are more likely to be in transcriptional modules than non-DE genes.
This is realized through the standard error term (denominator) of
the SAGAT score (see Materials and Methods). For a given gene in
a module (eigengene), the standard error for that gene’s mean
expression difference receives contributions from measurements of
the other genes in that module, leading to a smaller error (more
precise estimate of expression). Thus, genes in modules will on
average have slightly boosted SAGAT scores compared to genes
acting in isolation. In the process of characterizing modularity of the
HGU95Av2 knowledge set to parameterize our simulation, we have
discoveredthat DEgenesaremore likelyto beinmodulesthan non-
DE genes. Given that the performance improvements in the
letrozole treatment and colorectal cancer datasets were similar to
the prostate cancer case, we expect this feature of DE genes (and the
corresponding performance improvement by SAGAT) to be
generalizable to a wide variety of biological datasets. To support
this hypothesis, we note that genes which are frequently
differentially expressed are more likely to be associated with a
disease [54], and genes implicated in the same disease show higher
levels of coexpression (modularity) than randomly selected genes
[55].
A closer look at the functional form of the SAGAT score shows
its similarity to versions of the t-statistic, including the limma t and
SAM [39,56]. The difference between these metrics lies in their
method for calculating the standard error of each gene’s mean
expression difference. Though the limma t-statistic borrows
information for calculating this term from other genes, SAGAT
is the only approach that identifies and uses expression
dependencies between genes in the computation of gene-wise
variances. Fortunately, this addition is not computationally
expensive, as SAGAT utilizes efficient algorithms. Eigengenes
are identified using SVD, which must only be run once per
knowledge compendium. Computation of the SAGAT score
requires projection of a small (with respect to the size of the
knowledge) dataset into eigengene space followed by a simple dot
product for each gene. Practically, the running time of SAGAT is
approximately the same as that of related methods like the limma t-
statistic. We note, however, that the distribution of the SAGAT
score is complex, and unlike the t-statistic, it does not provide for a
straightforward estimation of statistical significance. Thus, we
advocate data permutation-based methods (similar to those used
by SAM) to calculate SAGAT p-values.
Use of SAGAT does require some explicit assumptions about
microarray knowledge. First, we assume that (detectable) multi-
gene transcriptional modules give rise to the expression values in a
compendium of microarray knowledge. Previous work [12–18]
detecting reproducible, biologically plausible transcriptional mod-
ules (along with results from our characterization of the
HGU95Av2 compendium) suggest that this is a valid assumption.
Second, representing the transcriptional levels of each gene as a
weighted combination of eigengene levels assumes that each gene’s
expression can be modeled in a linear fashion. While some
evidence exists to support this assumption [57], it is more realistic
that expression is a non-linear phenomenon. Nevertheless, linear
approximations have proven useful and even quite accurate in the
modeling of non-linearity [58]. We find empirical support for this
accuracy in the coherence of the GO terms significantly enriched
in eigengenes of the HGU95Av2 compendium. Third, though
SVD does not make any distributional assumptions about the
knowledge, the analytical derivation of the SAGAT score requires
the eigengene expressions to be statistically independent. When
the underlying eigengenes are distributed as multivariate normal
(MVN) random variables, they will exhibit independence, but
otherwise this may not be the case. Given that we did not explicitly
enforce this assumption in either the simulated data (here, genes
were MVN, not eigengenes) or the highly replicated real datasets,
this assumption does not appear to be detrimental to SAGAT
performance.
An implicit assumption in the use of prior microarray
knowledge to inform a novel dataset is that the expression
dependencies from the knowledge are conserved in the novel
dataset. In a worst-case scenario, a novel dataset would exhibit a
transcriptional response completely unlike anything assayed
previously. Given the modular nature of transcription, we expect
this to be unlikely, and the favorable performance of SAGAT on
three independent biological datasets supports this assertion.
Additionally, as even more microarray experiments are performed
and their data become available, the likelihood of such a scenario
occurring will tend to zero.
As SAGAT requires a large compendium of microarray
knowledge, it is worth examining potential biases in currently
available compendia. Due to their popularity among researchers,
the vast majority of publicly available human microarray datasets
are from Affymetrix platforms. Thus, the three compendia and
highly replicated datasets used in this study represent the three
most popular human Affymetrix GeneChips. One concern would
be that a non-biological bias (perhaps due to cross-hybridization
between specific probesets) exists in Affymetrix data which cannot
be detected and removed without considering data derived from
other platforms. This might lead to artifactual coexpression
relationships. Another concern would be that the dependency
information inferred from Affymetrix microarray knowledge is not
extensible to non-Affymetrix datasets, due to differences in
probesets or the artifactual coexpression phenomenon discussed
above. While these concerns may have some merit, we note that in
applying SAGAT to a novel insulin resistance dataset we
incorporated microarray knowledge from an Affymetrix platform
with data from Affymetrix, Illumina, and Agilent platforms. Given
the ability of SAGAT to correctly identify novel DE genes in this
case, we do not believe such a large Affymetrix-specific bias is
present.
Finally, as the value for parameter M (specifically, the fraction
M/P—see Materials and Methods) was set for all three Affymetrix
compendia based on performance observed using the HGU95Av2
compendium, there is an implicit assumption that the optimal
parameter value is identical between platforms. We evaluated this
SAGAT
PLoS Computational Biology | www.ploscompbiol.org 10 March 2010 | Volume 6 | Issue 3 | e1000718by testing SAGAT on several data subsets from the HGU133A
and HGU133plus2.0 platforms across a range of M values. Results
suggest that a value of M that is approximately half the number of
arrays in the compendium is nearly optimal for all three
compendia (not shown). Nevertheless, more principled approaches
of effectively choosing platform-specific values for M likely exist,
and future work will include identifying these approaches.
We provide SAGAT as an R package (sagat), which is available
at https://simtk.org/home/sagat. The package includes all
necessary functions to run the method along with preprocessed
versions of the W matrix for the three Affymetrix platforms
analyzed in this work. Given its abilities to improve the prediction
of DE genes, we expect that SAGAT will be useful to microarray
researchers studying a wide range of biological phenomena.
Materials and Methods
Ethics Statement
The insulin resistance study was approved by the Stanford
University Human Subjects Committee and the National Institute
of Digestive Diseases and Kidney Disease (NIDDK) Institutional
Review Board, and all subjects gave written informed consent.
Modularity of Gene Expression Data
We downloaded all available expression data for the Affymetrix
HGU95Av2 microarray (GPL91) from the Gene Expression
Omnibus (GEO: http://www.ncbi.nlm.nih.gov/geo/) in August
2007. These data are hereafter referred to as ‘‘knowledge’’, or a
knowledge compendium. The Robust Multi-array Average (RMA)
algorithm was first used to compute averages between probes in a
probeset. Probesets were then mapped to a non-redundant list of
Entrez Gene IDs (provided by the Bioconductor R package
hgu95av2 version 1.16.0), and expression values for multiple
probesets of the same gene were averaged using an arithmetic
mean. This resulted in a matrix of 9105 genes by 4440 arrays,
which is available for download at https://simtk.org/home/sagat.
We log transformed and quantile normalized the arrays to ensure
that they were on the same scale, and we computed the gene-gene
covariance matrix across all 4440 arrays, ignoring missing values.
In order to simplify characterization of the covariance structure,
we discretized the covariance matrix such that diagonal entries
and entries whose absolute value was greater than the mean
covariance value (.25) were set to one, and all others were set to
zero. We then hierarchically biclustered the rows and columns of
the binarized covariance matrix (using a distance metric of
1{binary covariance ½  and complete linkage) to enable visuali-
zation of gene groups with significant covariances. Here, we define
an expression module as a group of genes of size §15, identified
upon hierarchical biclustering of the covariance matrix, whose
pairwise binarized covariance values are all nonzero.
To test whether the observed modularity was due to chance,
we generated 100 permuted versions of the knowledge matrix,
whereby the columns of each row were permuted independently of
the other rows. We followed the subsequent steps of calculating
covariance, discretizing, and clustering as above, and we counted
the number of diagonal covariance clusters containing §15 genes
(i.e. expression modules).
To characterize expression modularity with respect to differen-
tially expressed (DE) or non-DE genes, we coupled the
HGU95Av2 compendium with a human prostate cancer micro-
array dataset [38]. Beginning with the clustered, binarized
covariance matrix of Figure 1B, we generated five 1000-gene
covariance matrices by randomly subsetting the full matrix. In
each one, we zeroed all covariance values in off-diagonal clusters
and those in diagonal clusters with fewer than five genes (in the
1000-gene matrix, we relax the cutoff for expression modules to
five genes). We calculated the mean number of genes per module
in the remaining covariance modules across the five matrices and
used this for simulating new compendia (details below). Using the
prostate cancer dataset, we identified DE genes as those having a
limma t-statistic with FDR ƒ:05 (calculated with the limma R
package version 2.8.1). We split each of the five covariance
matrices above into DE or non-DE subsets, and we calculated the
mean percentages of genes in covariance modules for each. These
values were also used for simulating compendia (below).
Singular Value Decomposition (SVD) of Gene Expression
Data
An overview of the SVD procedure is illustrated in Figure 7A. In
equation form, SVD transforms an N|P (genes6arrays) knowl-
edge matrix X into the product of three matrices U, S, and V:
X~U|S|VT ð1Þ
where | and
T represent matrix multiplication and transposition,
respectively. Asdetailed in[22], the dimensions of U, S, and VT are
genes6eigenarrays, eigenarrays6eigengenes, and eigengenes6ar-
rays, respectively. We follow the notation used in [59] and treat the
dimensions of the product SVT as ‘‘scaled eigengenes’’6arrays. As
SVD requires complete data, we either exclude arrays of the
knowledge matrix with missing values (if fewer than 10% of the total
numberof arrays areincomplete) or imputemissing values usingthe
K-nearest neighbor algorithm implemented in the impute R package
(version 1.6.0) [24]. We center and scale the rows of the complete
data matrix and run the svd R function.
To confirm the validity of an eigengene theory of gene expre-
ssion, we first ran SVD on the HGU95Av2 knowledge matrix with
missing values imputed. We then identified enriched Biological
Process Gene Ontology terms for each eigengene by applying the
Kolmogorov-Smirnov statistic (implemented in the topGO R
package version 1.2.1). Specifically, within each eigengene, all
9105 genes were ranked (in descending order) by the magnitudes
of their weights (determined from the appropriate column of U).
GO terms significantly enriched at the top of each ordered list
were then identified using the getSigGroups R function.
SAGAT—SVD Augmented Gene Expression Analysis Tool
SVD constructs a linear relationship between genes and
eigengenes such that each gene’s expression can be formulated
as a linear combination of the eigengene expressions (Figure 7B).
We can explicitly represent this in equation form by approximat-
ing (1) as follows:
X&W|E ð2Þ
where W is simply a matrix containing the first M columns of U (M
most significant eigenarrays), and E is the product of the first M
rows of matrix S with VT. Intuitively, E represents the knowledge
matrix X transformed from array space into eigenarray space, and
W provides the map between genes and scaled eigengenes. Given
a novel dataset D with m replicates (referred to as ‘‘data’’), we
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transformed into eigengene space. We obtain a mathematically
rigorous solution to (3) by premultiplying both sides by the
transpose of W. This is possible due to the orthogonality properties
of SVD and is equivalent to a projection using the pseudoinverse
of W. Such a projection gives the optimal (in the least squares
sense) approximation of dataset D in terms of the knowledge set X.
We note that pseudoinverse projection has previously been
successfully used in other areas of microarray analysis, particularly
with respect to noise reduction in data [29,30,60]. Knowledge of
ED (and D) allows us to calculate a mean log expression ratio for
each gene gk (  e egk) and a log expression ratio sample variance for
each eigengene (~ s s2
hi) (Figure 7C).
To perform hypothesis tests for differential expression, we
created a probabilistic model for each gene’s mean log expression
ratio   e egk. The properties of SVD allow us to approximate this
quantity in the following manner:
  e egk&mgkz
X M
i~1
wgk,hi|  ~ e e ~ e ehi
  
ð4Þ
where & implies ‘‘approximately equal to’’, | represents scalar
multiplication, mgk represents the unknown true mean log
expression ratio of gene gk, M is the number of eigengenes used
to reconstitute the gene expressions, the weights wgk,hi
no
come
from W, and the   ~ e e ~ e ehi’s are mean log ratios for mean-centered
eigengenes (assumed to be normally distributed):






where * implies ‘‘distributed as’’, N(:) specifies a normally
distributed random variable, and s2
hi represents the population
expression variance for eigengene hi. Thus, the   e egk’s acquire the
following distribution:
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By using the empirical Bayes variance estimators ~ s s2
hi (calculated
using the limma R package (version 2.8.1) [39]) in place of the
unknown s2
hi’s, we arrive at the test-statistic ^ t tgk for gene gk,
analogous to the one sample t-statistic:
^ t tgk~







v u u u t
ð7Þ
This ‘‘SAGAT score’’ borrows information regarding expres-
sion variability for each gene from covarying genes via their shared
eigengenes. Though the statistical model used to derive this metric
assumes normally distributed eigengene log expression ratios, it
will still provide quantitatively useful scores when this assumption
is not met. In the case when m~1, the ~ s s2
hi’s are undefined and a
slight modification is required. We discovered that the following
form of the SAGAT score gave performance consistent with that
achieved on datasets with m greater than 1:
^ t tgk~






v u u u t
ð8Þ
where ehi is the single log ratio for eigengene i calculated by
transforming the data into eigengene space and D:D implies absolute
value.
Figure 7. Overview of SAGAT method. (A) Schematic of SVD
applied to a matrix of microarray knowledge. The dimensions of matrix
SVT are ‘‘scaled eigengenes’’ by arrays. The weight matrix W,
consisting of the first M columns of U, is used in subsequent steps.
(B) Graphical depiction of SVD model, whereby each gene’s expression
is a weighted combination of underlying eigengene expressions with
weights given by W. (C) SAGAT transforms a dataset of interest into
eigengene space by premultiplying the data matrix by the transpose of
the weight matrix W. Both the original and transformed data matrices
are subsequently used to calculate the SAGAT statistic (in the forms of
  e egk
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unknown, so we treat it as a parameter to be learned from data.
Details of the learning procedure for simulated and highly
replicated real data are found below in the corresponding sections.
Simulation Study
We simulated 1000-gene compendia of microarray knowledge
by generating 1000 multivariate normal random variables (using
the mvrnorm function in the R MASS package version 7.2–48).
The mean vector used for the simulation was derived from sample
means of 1000 random genes from the HGU95Av2 compendium;
the covariance matrix contained all zeros except in positions
needed to create the desired modularity structures (Figure 2). In
these positions, we used a covariance value of 4, which was chosen
to be large enough to generate knowledge compendia that led to
noticeable differences in SAGAT performance. We simulated
1000-gene microarray data with numbers of replicates ranging
from 1–15 using the procedure listed in [19], parameterized with
values derived from the prostate cancer dataset. Each dataset was
engineered to contain 100 DE genes.
We ran SVD on each simulated compendium and used the
resultant W matrix to test SAGAT on all combinations of data and
knowledge. To estimate M, we evaluated SAGAT performance as
a function of varying M across a range of simulated data (1–15
replicates) and knowledge compendia (all configurations between
Figures 2A and B). We chose a value of M that gave optimal
performance across all tested configurations; this value was used
for all subsequent tests on simulated data. We compared the results
of these tests (in the form of ROC AUC and TPR at a fixed FPR
of .05) to that achieved by fold change to determine the range of
data/knowledge configurations in which SAGAT outperformed
fold change.
Highly Replicated Real Datasets
We evaluated SAGAT’s potential to improve DE gene
prediction on real data by testing the method on three highly
replicated datasets. This approach is similar to that used by [11],
except that we choose area under the ROC curve and true positive
rate as our evaluation metrics. The first dataset, listed above,
measures differences in expression between prostate cancer tissue
and matched non-cancer prostate [38]. This dataset measures
expression of 9105 genes (identified by mapping probe names to
Entrez Gene IDs as above) across 47 pairs of samples (‘‘replicates’’:
as Affymetrix arrays measure one RNA sample at a time, one
experimental replicate is equivalent to two arrays). The second
dataset compares breast cancer tissue before and after letrozole
treatment [61]. These data were collected across 58 pairs of
samples on the HGU133A Affymetrix platform, which measures
expression of 13410 Entrez Genes. The final dataset measures
expression differences between colorectal cancer tissue and
matched non-cancer tissue [62]. This dataset was generated for
32 pairs of samples on the HGU133plus2.0 Affymetrix platform,
which encompasses 20099 Entrez Genes. For each dataset we
determined truly DE genes by calculating either mean fold
changes or limma t statistics across all replicates and counting genes
with the largest scores (irrespective of sign) as DE. The number of
DE genes in each case was set to the number of genes whose t-
statistic was significant at a .05 FDR cutoff. We performed all
analyses using the limma R package (version 2.8.1).
To obtain knowledge for each dataset, we downloaded all
publicly available microarray datasets from GEO (minus the
highly replicated datasets listed above) for each of the correspond-
ing Affymetrix platforms. As mentioned above, the HGU95Av2
compendium contained 4440 arrays, while the HGU133A
(GPL96) and HGU133plus2.0 (GPL570) compendia consisted of
14476 and 12217 arrays, respectively (as of March 2008). For each
knowledge source, we either imputed missing data (HGU95Av2)
or excluded incomplete arrays (HGU133A, HGU133plus2.0) to
arrive at the number of arrays listed above. As with the above
datasets, we mapped probe names of each knowledge compendi-
um to the corresponding Entrez Genes. We ran SVD as detailed




GPL570, each containing the maximal number of
eigengenes.
We evaluated SAGAT on its ability to identify DE genes from
subsets of each dataset that best match the truly DE genes
discovered using all replicates. For each dataset, we generated the
maximal number of non-overlapping subsets of size 1, 2, 5, and 15
(14 for Letrozole treatment) replicates. We ran SAGAT on each
data subset with the appropriate W matrix (defined below),
calculated fold changes and limma t-statistics for comparison, and
computed the ROC AUCs and TPRs evaluated at FPR=.05 for
all three metrics with respect to the truly DE genes. We used the R
package ROCR (version 1.0–2) [63] for AUC and TPR
calculations.
To determine the optimal number of eigengenes (M parameter)
to use in the W matrices for each dataset, we tested all possible
numbers of eigengenes from 5 to 4400 (in multiples of 5) on several
subsets of the Prostate cancer dataset. The number of eigengenes
that gave the best performance overall was used as the value for
MGPL91, and the values for MGPL96 and MGPL570 were set such
that they yielded an identical fraction of M/P, where P is the total




GPL570 by only including the first M
columns of each to form WGPL91, WGPL96, and WGPL570,
respectively. We used these modified matrices in the SAGAT
analysis described above.
We also characterized SAGAT performance in terms of the
effective number of arrays added. For each of the highly replicated
datasets, we calculated ROC AUCs of the fold change metric
applied to all non-overlapping replicate subsets ranging in size
from 1 to the total number of replicates. These AUCs enabled us
to fit a ‘‘standard curve’’ for each dataset, from which we could
interpolate the mean number of arrays gained by using SAGAT
given initial numbers of 2, 4, 10, and 30 (28 for Letrozole dataset)
arrays [equivalent to 1, 2, 5, and 15 (14) replicates, respectively].
Comparison to related method
We compared SAGAT performance to that of the GEO
method, which was implemented as described in [11] using both
the standard method and ‘‘voting’’ scheme. The comparison was
made as above on subsets of the prostate cancer dataset, using the
HGU95Av2 compendium as knowledge. We also evaluated the
effect of smaller compendium sizes on SAGAT performance by
taking random subsets of 100 to 4000 arrays (10 subsets per size) of
the HGU95Av2 compendium and calculating the mean AUC
improvement over fold change across all subsets of the prostate
cancer dataset.
Insulin Resistance Dataset
We applied SAGAT to an unpublished biological dataset
investigating human insulin resistance. Briefly, 33 moderately
obese but otherwise healthy female patients were tested for insulin
resistance using a modified insulin suppression test [64]. RNA was
isolated from the adipose tissue of the 12 most and 12 least insulin
resistant patients and hybridized to three different microarray
platforms: Affymetrix HGU133plus2.0, Agilent G4112A, and
Illumina HumanRef-8 v2. The data from the Affymetrix platform
SAGAT
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the other two platforms were normalized using default algorithms
accompanying the respective feature extraction programs. Raw
data for each of the three platforms are available for download as
Datasets S1,S2,S3.
We first used the limma t-statistic to identify DE genes using the
data from each platform individually. To utilize data from all three
platforms simultaneously, we applied the method of Rank
Products to lists of genes from each platform ranked either by
fold change or SAGAT score (in both cases separating up and
downregulated genes).
Predicted DE genes were validated by quantitative RT-PCR
experiments. 200ng of total adipose tissue RNA was amplified
using the Ambion MessageAmp II aRNA Amplification Kit (cat
#AM1751) according to manufacturer’s instructions. 1ug of
amplified product was then used for quantitative PCR analysis using
Taqman primer/probe sets for ACTG2 (Entrez Gene ID: 72),
CSN1S1, FOSB, SELE, FAM150B (285016), PMP2, ATP1A2,
CXCR4, ELOVL6, FASN, SRGN, EPHX2 (2053), F2 (2147),
CEBPD (1052), and LIPG (9388) as well as Human b-actin
endogenous control. Primer/probe sets were purchased from Applied
Biosystems (Foster City, CA). Amplification was carried out in
triplicate on an ABI Prism 7900HT at 500C for 2 min and 950C for
10 min followed by 40 cycles of 950C for 15 s and 600C for 1 min. A
threshold cycle (CT value) was obtained from each amplification
curve and a DCT value was first calculated by subtracting the CT
value for b-actin from the CT value for each sample. A DDCT value
was then calculated by subtracting the DCT value of a single insulin-
sensitive subject (control). Fold-changes compared with the control
were then determined by raising 2 to the DDCT power.
We tested the significance of each gene’s qPCR-derived
expression differences using a one-sided Wilcoxon rank-sum test
(two-sided test was used for negative controls). Genes with p-values
smaller than a .05 threshold were considered significant.
Supporting Information
Figure S1 Comparison of SAGAT and the GEO method. Each
panel displays performance on the prostate cancer dataset. (A) The
fold change metric was used to rank genes for the gold standard.
SAGAT and the GEO method (both with HGU95Av2 compen-
dium) and fold change were run on all combinations of 1, 2, 5, and
15 replicate subsets and the performance improvement of SAGAT
and GEO over fold change displayed. (B) Identical conditions as
(A), with the limma t metric used to rank gold standard genes. (C)
and (D) Similar plots comparing SAGAT and the GEO voting
method, which requires two or more replicates to score genes. Fold
change and limma t metrics were used to rank gold standard genes
in (C) and (D), respectively. In all cases, SAGAT performs as well
or better than the GEO method.
Found at: doi:10.1371/journal.pcbi.1000718.s001 (1.72 MB TIF)
Figure S2 Effect of compendium size on SAGAT performance.
SAGAT was run on all subsets of the prostate cancer dataset using
randomly subset versions of the HGU95Av2 compendium ranging
in size from 100 to 4400 arrays. The mean AUC improvement
over the fold change method is displayed on the y-axis. Each
boxplot shows the results of using 10 random compendium subsets
of a given size. Though the rate of performance improvement
lessens as the number of arrays in the compendium increases,
extrapolation suggests that the addition of more arrays will lead to
further improvement.
Found at: doi:10.1371/journal.pcbi.1000718.s002 (7.56 MB TIF)
Figure S3 SAGAT true positive rate for four simulated data-
knowledge configurations. In each panel, both SAGAT and the
fold change metric were applied to 200 simulated datasets
consisting of either one [(A) and (B)] or 15 replicates [(C) and
(D)]; the true positive rate (TPR) improvement (evaluated at a
fixed false positive rate of .05) achieved by SAGAT over fold
change is displayed for each. In (A) and (C), a simulated knowledge
compendium matching Figure 2A was used by SAGAT; in (B) and
(D) the simulated knowledge corresponds to Figure 2B. SAGAT
performance improvements measured by TPR closely resemble
those measured by AUC (displayed in Figure 3).
Found at: doi:10.1371/journal.pcbi.1000718.s003 (1.09 MB TIF)
Figure S4 SAGAT, fold change, and limma t TPR performance
on subsets of three highly replicated human datasets. In each panel,
the gold standard was defined as the top 1122, 588, and 6002
highest scoring genes for the prostate cancer, letrozole treatment,
and colorectal cancer datasets, respectively. (A) The fold change
metric was used to rank genes for the gold standard. SAGAT (with
HGU95Av2 compendium), fold change, and limma t were run on
all combinations of n=1, 2, 5, and 15 replicate subsets and the
performance improvement (measured by TPR evaluated at a fixed
false positive rate of .05) of SAGAT and limma t over fold change
displayed. Limma t requires two or more replicates to score genes.
(B) Identical conditions as (A), with the limma t metric used to rank
gold standard genes. (C) and (D) Similar plots for the letrozole
treatment (HGU133A compendium) and colorectal cancer
(HGU133plus2.0 compendium) datasets, respectively. Fold change
was used to rank gold standard genes in these panels. SAGAT
performance improvements measured by TPR closely resemble
those measured by AUC (displayed in Figure 5).
Found at: doi:10.1371/journal.pcbi.1000718.s004 (1.55 MB TIF)
Dataset S1 Affymetrix Insulin Resistance data table.
Found at: doi:10.1371/journal.pcbi.1000718.s005 (6.12 MB
TXT)
Dataset S2 Agilent Insulin Resistance data table.
Found at: doi:10.1371/journal.pcbi.1000718.s006 (8.30 MB ZIP)
Dataset S3 Illumina Insulin Resistance data table.
Found at: doi:10.1371/journal.pcbi.1000718.s007 (3.04 MB
TXT)
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